CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Incanthera PLC is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Incanthera PLC
76 King Street
Phone: +44 1618175005p:+44 1618175005 MANCHESTER, M2 4NH  United Kingdom Ticker: INCINC
Business Summary
Incanthera plc is a United Kingdom-based dermatology and oncology therapeutics company. The Company's is focused on developing a range of dermatological applications utilizing its unique formulation and delivery technologies to meet the unmet needs in the skincare market. Skin + CELL is the Company’s luxury skincare brand utilizing the advanced formulation and delivery expertise, to bring scientifically proven formulations to cosmetics. Skin + CELL's formulations, enriched with targeted bioactive B3 (an activated form of niacinamide) are delivered directly into the skin's cells to optimize and protect cellular health, energy and protective capabilities. Skin + CELL's luxury skincare range extends across face, body, hand, face serum and eye serum.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/20233/31/2023Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman TimothyMccarthy 66 10/23/2017 10/23/2017
Chief Executive Officer, Director Simon J.Ward 10/23/2017 10/23/2017
Chief Financial Officer LauraBrogden
Head of Communications and Company Secretary SuzanneBrocks 1/1/2022 1/1/2022
Senior Independent Non-executive Director CarolineMurray 2/23/2022 2/23/2022

General Information
Number of Employees: 8 (As of 3/31/2023)
Outstanding Shares: 77,824,166 (As of 9/30/2023)
Stock Exchange: AQS


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, May 1, 2024